Article -> Article Details

Managing Type 2 diabetes rarely comes down to a single drug. Galvus Met brings two proven therapies into a single tablet — addressing the condition from two different angles at the same time. 

1.  What Is Galvus Met? 

Galvus Met is an oral combination medicine used to treat people aged 18 years or older who have Diabetes Type_2. Galvus Met is sold under the trademark name of Eucrea in other countries by Cipla Pharma Ltd., India and in USA by Merck LLC. Galvus Met is a combination of two different molecules that can be given as one dose taken by mouth.

The first molecule in Galvu Met is Vildagliptin, which is a member of the Dipeptidyl Peptidase (DPP-4) Inhibitor class of drugs that decrease blood sugar levels by increasing the production of insulin and lowering glucagon levels in the body. The second molecule in Galvus Met is Metformin Hydrochloride, available in three strengths: 500mg, 850mg, and 1000mg. Metformin is used to reduce blood glucose levels by improving insulin sensitivity and reducing glucose production from the liver.

Galvus Met is considered a film-coated tablet and is taken by mouth (orally) usually two times per day; was intended to be taken with food and although is part of the general class of oral anti-diabetic products does fall under second-line to add-on to the treatment of diabetes when patients can no longer manage their blood sugars through diet and exercise alone. 

2. Two Active Ingredients and How They Work Together 

Rather than addressing blood glucose dysregulation using just one approach, Galvus Met works via two separate mechanisms. By understanding how each of these agents works, patients can see why the combination is often more effective than using either agent by itself.

1. Vildagliptin — The Incretin Amplifier

Vildagliptin works by inhibiting the activity of DPP-4, which is an enzyme that normally breaks down incretin hormones (GLP-1 and GIP) shortly after they’re released into the bloodstream. Because vildagliptin protects incretin hormones, they remain active and stimulate the pancreas to secrete insulin based on the level of glucose in the body. This is important because it only occurs when there is an increase in glucose; therefore, it minimizes the risk of hypoglycemia occurring. It also inhibits glucagon which instructs the liver to produce and secrete more glucose into the blood stream.

2. Metformin — An Insulin-Sensitizing Medication

For many years, clinicians have been using a drug called Metformin to help people with diabetes control blood sugar levels. One of the primary ways Metformin works is by helping the liver produce less glucose (sugar) when someone is in a fasting state (or overnight). In addition to this action, Metformin increases how well muscle and fat cells respond to insulin, therefore allowing these cells to take up more glucose from the bloodstream. Because Metformin does not increase the release of insulin from the pancreas, it has a very low risk of causing hypoglycemia (low blood sugar) on its own.

3. Combination versus Monotherapy

Metformin and Vildagliptin complement each other well due to their different but complementary actions. Vildagliptin increases Rajib's insulin levels after he eats, which helps lower his post-meal glucose levels. At the same time, Metformin decreases Rajib's liver production of glucose, which decreases his overnight glucose levels. So, by using both medications together, Rajib can maintain normal glucose levels throughout the day, for example, before breakfast, after breakfast, at lunchtime, and overnight.

3. What Can Patients Actually Expect?

When a practitioner prescribes Galvus Met for their patients, they are relying on ample evidence to support its pharmacological skill as well as many of the benefits derived from its use.

Possibly more importantly for patients over time will be prevention of complications. With the continued maintenance of an HbA1c level in target range through the use of Galvus Met, there is cumulative reduction of damage caused to small blood vessels and nerves by chronically elevated sugar levels. Over time, this should correspond with a significant decline in their likelihood of developing diabetic neuropathy (nerve damage affecting the extremities), nephropathy (kidney damage), and retinopathy (damage to the retina affecting vision).

1. Key Clinical Advantages at a Glance

• Improved HbA1c — long-term blood sugar marker — toward target range

• Lower hypoglycemia risk compared to sulfonylurea-based therapies

• Reduced post-meal glucose spikes through demand-driven insulin release

• Stabilised fasting blood glucose via reduced liver glucose output

• Weight-neutral profile — typically does not contribute to weight gain

• Simplified pill schedule — two drugs, one tablet, twice daily

• Long-term protection against diabetes-related complications

• Well-tolerated in the majority of adult patients at standard doses

4. Who Is This Medication Prescribed For?

Galvus Met is not a "first line" diabetes drug; nor should it be used solely as the initial therapy. It fills a role in the overall management of patients with Type 2 diabetes where previous therapies have not achieved adequate levels of control.

Examples of typical patients include:

Adults with Type 2 diabetes whose blood glucose is still above acceptable levels while taking Metformin alone.

Patients taking Metformin (as one medication) and Vildagliptin (as another medication) separately and want their medications to be easier to take.

Patients who are currently using another medication regimen and are changing from that practitioner's care to your care with your approval to start Galvus Met.

Important: Not for Type 1 Diabetes

Galvus Met is strictly indicated for Type 2 diabetes mellitus only. It should not be used for Type 1 diabetes, diabetic ketoacidosis, or as a substitute for insulin in any insulin-dependent scenario.

It is also worth noting that Galvus Met is only initiated after diet and exercise modifications have proven insufficient. The medication works most effectively when lifestyle habits remain prioritised alongside pharmacological therapy.

5. Understanding the Side Effect Profile

Like all medicines, Galvus Met carries a side effect profile that patients and caregivers should be familiar with. The good news is that the majority of side effects are mild, transient, and largely attributable to the Metformin component, especially during the first few weeks of treatment as the digestive system adjusts.

Common — Digestive

• Nausea or queasiness, especially initially

• Loose stools or diarrhoea

• Abdominal discomfort or bloating

• Metallic or unusual taste in the mouth

• Reduced appetite during dose initiation

Common — General

• Headache or mild dizziness

• Fatigue or sense of tiredness

• Mild upper respiratory symptoms

• Mild tremor in some individuals

• Increased perspiration occasionally

Less Common

• Skin rash or mild itching

• Joint or muscle discomfort

• Swelling (oedema) — rare

• Mild low blood sugar (in combination)

• Vitamin B12 reduction over long-term use

Serious — Seek Medical Help

• Lactic acidosis — rare but life-threatening

• Severe allergic reactions (hives, swelling)

• Severe hypoglycemia with other agents

• Pancreatitis — very rare occurrence

Recognise Lactic Acidosis Early

Although rare, lactic acidosis is the most serious risk associated with Metformin. Warning signs include unusual muscle pain, difficulty breathing, stomach discomfort, feeling cold, dizziness, and irregular heartbeat. Seek emergency medical attention immediately if these symptoms occur together.

Key Precautions Before and During Treatment

Galvus Met should be monitored more closely in certain patient populations. Careful monitoring of kidney function is an important aspect of the use of Metformin because Metformin builds up in the body due to poor ability of the body to remove it from the bloodstream, thereby raising the risk of lactic acidosis. Therefore, patients taking Galvus Met should have their kidney function tests (serum creatinine, eGFR) performed at least once a year; patients with pre-existing renal dysfunction should have these tests performed on a more frequent basis.

The liver should be monitored as well, since Vildagliptin is metabolised by the liver. Patients with moderate to severe liver impairments should probably avoid using this combination of medications.

Alcohol use should also be discussed separately. Regularly drinking large amounts of alcohol can cause an increased risk of developing lactic acidosis from Metformin and can also hide the signs of low blood sugar (hypoglycaemia) from patients. Therefore, it is strongly recommended that patients taking Galvus Met limit or avoid using any amount of alcohol.

A Note on Using This Guide

This blog article is written for general educational purposes and is not a substitute for personalised medical advice. Galvus Met is a prescription medication and should only be taken under the direction of a qualified healthcare professional who has reviewed your full medical history, current medications, and individual circumstances.

Always consult your doctor or pharmacist before starting, stopping, or changing any medication.

-OnlineGenericMedicine.com